EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma [PDF]
Cell Death and DiseaseT-cell lymphoma (TCL) is a rare subtype of non-Hodgkin lymphoma (NHL) that is associated with a poor prognosis. Although HDAC inhibitors have been approved for TCL treatment for several years, their expected therapeutic efficacy remains unmet in some ...
Jiajin Wu +11 more
doaj +2 more sources
Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-Cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC) [PDF]
PharmaceuticalsPancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreatic cancer characterized by therapy resistance and early metastasis, resulting in a low survival rate.
Katja Schiedlauske +7 more
doaj +2 more sources
4-Hexylresorcinol Inhibits Class I Histone Deacetylases in Human Umbilical Cord Endothelial Cells
Applied Sciences, 2021 Histone deacetylases (HDACs) are key enzymes for post-translational modification and influence on various cellular activities. Thus, HDACs are associated with many diseases and their inhibitors have clinical significance.
Jwa-Young Kim +4 more
doaj +1 more source
Frontiers in Oncology, 2023 BackgroundThe overall survival of peripheral T-cell lymphoma (PTCL) is dismal. Histone deacetylase (HDAC) inhibitors have exhibited promising treatment outcomes for PTCL patients. Therefore, this work aims to systematically evaluate the treatment outcome
Peipei Yang +12 more
doaj +1 more source
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
Frontiers in Oncology, 2021 We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells.
Jane L. Roberts +3 more
doaj +1 more source
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
Molecules, 2020 With five histone deacetylase (HDAC) inhibitors approved for cancer treatment, proteolysis-targeting chimeras (PROTACs) for degradation of HDAC are emerging as an alternative strategy for HDAC-targeted therapeutic intervention.
Jiangying Cao +7 more
doaj +1 more source
Azumamides A-E: Isolation, Synthesis, Biological Activity, and Structure–Activity Relationship
Molecules, 2022 Cyclic peptides are one of the important chemical groups in the HDAC inhibitor family. Following the success of romidepsin in the clinic, naturally occurring cyclic peptides with a hydrophilic moiety have been intensively studied to test their function ...
Sooheum Jo +4 more
doaj +1 more source
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. [PDF]
PLoS ONE, 2010 BACKGROUND: Lung cancer is the leading cause of cancer mortality worldwide, yet the therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective.
Yen-An Tang +8 more
doaj +1 more source
Cell Death and Disease, 2022 Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors.
Jianling Bi +7 more
doaj +1 more source
Redox Biology, 2021 Epithelial-to-mesenchymal transition (EMT) is an essential mechanism for development and wound healing, but in cancer it also mediates the progression and spread of aggressive tumors while increasing therapeutic resistance.
Thais Oliveira +5 more
doaj +1 more source